Telemonitoring-based feedback improves adherence to non-vitamin K antagonist oral anticoagulants intake in patients with atrial fibrillation

被引:47
|
作者
Desteghe, Lien [1 ,2 ]
Vijgen, Johan [2 ]
Koopman, Pieter [2 ]
Dilling-Boer, Dagmara [2 ]
Schurmans, Joris [2 ]
Dendale, Paul [1 ,2 ]
Heidbuchel, Hein [1 ,3 ,4 ]
机构
[1] Hasselt Univ, Fac Med & Life Sci, Martelarenlaan 42, B-3500 Hasselt, Belgium
[2] Jessa Hosp, Heart Ctr Hasselt, Stadsomvaart 11, B-3500 Hasselt, Belgium
[3] Univ Antwerp, Dept Cardiol, Wilrijkstr 10, B-2650 Edegem, Belgium
[4] Antwerp Univ Hosp, Wilrijkstr 10, B-2650 Edegem, Belgium
关键词
Non-vitamin K antagonist oral anticoagulants; Adherence; Telemonitoring; Atrial fibrillation; MEDICATION ADHERENCE; THERAPY; PERSISTENCE; STROKE; RISK; METAANALYSIS; MANAGEMENT; REGIMENS; IMPACT;
D O I
10.1093/eurheartj/ehx762
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims To evaluate the effect of telemonitoring on adherence to non-vitamin K antagonist oral anticoagulants (NOACs) in atrial fibrillation (AF) patients. Methods and results A randomized, single-blind, crossover, controlled trial in 48 AF patients on once or twice daily (OD or BID) NOAC. The Medication Event Monitoring System tracked NOAC intake during three phases of 3 months each: daily telemonitoring, telemonitoring with immediate telephone feedback in case of intake errors, and an observation phase without daily transmissions. Unprotected days were defined as >= 3 or >= 1 consecutively missed doses for a BID or OD NOAC, respectively, or excess dose intake. Cost-effectiveness was calculated based on anticipated stroke reduction derived from patients' risk profile and measured intake. Persistence over the entire study was 98%. Telemonitoring-only already led to very high taking and regimen adherence (97.4% respectively 93.8%). Nevertheless, direct feedback further improved both to 99.0% and 96.8%, respectively (P < 0.001 respectively P =0.002). Observation without daily monitoring resulted in a significant waning of taking adherence (94.3%; P =0.049). Taking adherence was significantly higher for OD compared to BID NOAC, although unprotected days were similar. Feedback intervention had an incremental cost of (sic)344 289 to prevent one stroke, but this could be as low as (sic)15 488 in high-risk patients with low adherence and optimized technology. Conclusion Telemonitoring resulted in high NOAC adherence due to the notion of being watched, as evidenced by the rapid decline during the observation period. Feedback further optimized adherence. Telemonitoring with or without feedback may be a cost-effective approach in high-risk patients deemed poorly adherent.
引用
收藏
页码:1394 / 1403
页数:10
相关论文
共 50 条
  • [1] Telemonitoring based feedback improves adherence for non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
    Desteghe, L.
    Vijgen, J.
    Dilling-Boer, D.
    Koopman, P.
    Schurmans, J.
    Dendale, P.
    Heidbuchel, H.
    [J]. EUROPEAN HEART JOURNAL, 2016, 37 : 1044 - 1045
  • [2] Telemonitoring-based feedback improves adherence to non-vitamin K antagonist oral anticoagulants intake in patients with atrial fibrillation (vol 39, pg 1394, 2018)
    Desteghe, Lien
    Vijgen, Johan
    Koopman, Pieter
    Dilling-Boer, Dagmara
    Schurmans, Joris
    Dendale, Paul
    Heidbuchel, Hein
    [J]. EUROPEAN HEART JOURNAL, 2019, 40 (05) : 455 - 455
  • [3] Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation
    Plitt, Anna
    Ruff, Christian T.
    Giugliano, Robert P.
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2016, 30 (05) : 1019 - +
  • [4] Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Thrombocytopenia
    Janion-Sadowska, Agnieszka
    Papuga-Szela, Elbieta
    Lukaszuk, Robert
    Chrapek, Magdalena
    Undas, Anetta
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2018, 72 (03) : 153 - 160
  • [5] Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation
    Undas, Anetta
    Drabik, Leszek
    [J]. ANATOLIAN JOURNAL OF CARDIOLOGY, 2020, 23 (01): : 10 - 18
  • [6] Cessation of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
    Middeldorp, Melissa E.
    Gupta, Aashray
    Elliott, Adrian
    Kadhim, Kadhim
    Thiyagarajah, Anand
    Gallagher, Celine
    Hendriks, Jeroen
    Linz, Dominik
    Emami, Mehrdad
    Mahajan, Rajiv
    Lau, Dennis
    Sanders, Prashanthan
    [J]. HEART, 2021, 107 (12) : 971 - 976
  • [7] Adherence to oral anticoagulant therapy in patients with atrial fibrillation Focus on non-vitamin K antagonist oral anticoagulants
    Raparelli, Valeria
    Proietti, Marco
    Cangemi, Roberto
    Lip, Gregory Y. H.
    Lane, Deirdre A.
    Basili, Stefania
    [J]. THROMBOSIS AND HAEMOSTASIS, 2017, 117 (02) : 209 - 218
  • [8] Non-vitamin K antagonist oral anticoagulants in valvular atrial fibrillation
    Basaran, Ozcan
    Dogan, Volkan
    Sahin, Cem
    Biteker, Murat
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 212 : 357 - 357
  • [9] Non-Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation
    Fanaroff, Alexander C.
    Ohman, E. Magnus
    [J]. ANNUAL REVIEW OF MEDICINE, VOL 70, 2019, 70 : 61 - 75
  • [10] Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation
    Giugliano, Robert P.
    [J]. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24 : A1 - A10